Surrozen (SRZN) Depreciation & Amortization (CF) (2020 - 2026)
Surrozen (SRZN) recorded quarterly Depreciation & Amortization (CF) of $65000.0 in Q1 2026, up 44.44% quarter-over-quarter from $45000.0 in Q4 2025, and down 77.89% on a YoY basis from $294000.0 in Q1 2025.
Surrozen (SRZN) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Surrozen's Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $65000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 77.89% year-over-year to $65000.0; the TTM figure through Mar 2026 stood at $307000.0 (down 76.42% YoY), while the FY2025 annual figure was $537000.0, down 61.64% from the prior year.
- Depreciation & Amortization (CF) was $65000.0 for Q1 2026 at Surrozen, up from $45000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $534000.0 in Q1 2022 to a low of $45000.0 in Q4 2025.
- Historically, Depreciation & Amortization (CF) has averaged $347117.6 across 5 years, with a median of $392000.0 in 2024.
- The sharpest annual moves came in 2023 and 2025: Depreciation & Amortization (CF) increased 4.65% in 2023, then slumped 83.93% in 2025.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $523000.0 in 2022, then fell by 15.87% to $440000.0 in 2023, then slumped by 36.36% to $280000.0 in 2024, then plunged by 83.93% to $45000.0 in 2025, then soared by 44.44% to $65000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $65000.0 (Q1 2026), $45000.0 (Q4 2025), and $60000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 1,395.22 |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 429,663.65 |
| 10 | Surrozen | 255,659.15 | -106.65 Mn | - | 65,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 65,000.00 |
| Mar 31, 2026 | 65,000.00 |
| Dec 31, 2025 | 45,000.00 |
| Dec 31, 2025 | 45,000.00 |
| Sep 30, 2025 | 60,000.00 |
| Sep 30, 2025 | 60,000.00 |
| Jun 30, 2025 | 137,000.00 |
| Jun 30, 2025 | 137,000.00 |
| Mar 31, 2025 | 294,000.00 |
| Mar 31, 2025 | 294,000.00 |
| Dec 31, 2024 | 280,000.00 |
| Dec 31, 2024 | 280,000.00 |
| Sep 30, 2024 | 342,000.00 |
| Sep 30, 2024 | 342,000.00 |
| Jun 30, 2024 | 386,000.00 |
| Jun 30, 2024 | 386,000.00 |
| Mar 31, 2024 | 392,000.00 |
| Mar 31, 2024 | 392,000.00 |
| Dec 31, 2023 | 440,000.00 |
| Dec 31, 2023 | 440,000.00 |